Avinger,Inc. (NASDAQ:AVGR) Files An 8-K Other Events

Avinger,Inc. (NASDAQ:AVGR) Files An 8-K Other Events
Item 8.01. Other Events.

Story continues below

In conjunction with its participation at an investor conference on June4, 2018, Avinger,Inc. (the “Company”) disclosed updated information concerning the number of shares of its common stock and preferred stock outstanding. As of May30, 2018, there were 9,068,372 shares of the Company’s common stock, 41,800 shares of the Company’s SeriesA preferred stock and 2,155 shares of the Company’s SeriesB preferred stock outstanding. Each share of SeriesA preferred stock and SeriesB preferred stock is presently convertible into 500 shares of common stock. Assuming the full conversion of all outstanding shares of the Company’s preferred stock, the Company would have had approximately 31 million shares of common stock outstanding as of May30, 2018. As of May30, 2018, the Company also had 8,989,500 Series1 warrants and 8,709,500 Series2 warrants outstanding. The Series1 and Series2 warrants are each exercisable for common stock at $2.00 per share. The foregoing descriptions of the SeriesA preferred stock, SeriesB preferred stock, Series1 warrants and Series2 warrants are qualified in their entirety by reference to the Certificate of Designation of Preferences, Rights and Limitations of SeriesA Convertible Preferred Stock, Certificate of Designation of Preferences, Rights and Limitations of SeriesB Convertible Preferred Stock and the Formof Series1/2 Common Stock Purchase Warrant, each of which has been previously filed and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

(1) Previously filed as an Exhibitto Amendment No.2 to the registrant’s Registration Statement on FormS-1 (File No.333-222517) filed with the Securities and Exchange Commission on February12, 2018, and incorporated by reference herein.

(2) Previously filed as an Exhibitto Amendment No.3 to the registrant’s Registration Statement on FormS-1 (File No.333-222517) filed with the Securities and Exchange Commission on February13, 2018, and incorporated by reference herein.


About Avinger,Inc. (NASDAQ:AVGR)

Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system. The Company manufactures and sells a suite of products in the United States and certain European markets. The Company’s products include Lightbox imaging console, as well as its Wildcat, Kittycat and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO). The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products, including Ocelot, Ocelot PIXL, Ocelot MVRX and Pantheris.

An ad to help with our costs